Z Shahrokh
Overview
Explore the profile of Z Shahrokh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
939
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leong S, Deforge L, Presta L, Gonzalez T, Fan A, Reichert M, et al.
Cytokine
. 2001 Dec;
16(3):106-19.
PMID: 11741351
A neutralizing anti-interleukin-(IL-)8 monoclonal antibody was humanized by grafting the complementary determining regions onto the human IgG framework. Subsequent alanine scanning mutagenesis and phage display enabled the production of an...
2.
Papac D, Shahrokh Z
Pharm Res
. 2001 Jun;
18(2):131-45.
PMID: 11405282
This review highlights the many roles mass spectrometry plays in the discovery and development of new therapeutics by both the pharmaceutical and the biotechnology industries. Innovations in mass spectrometer source...
3.
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al.
Nat Med
. 2001 Apr;
7(4):383-5.
PMID: 11283636
No abstract available.
4.
Koumenis I, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G
Int J Pharm
. 2000 Mar;
198(1):83-95.
PMID: 10722953
By covalently attaching biocompatible polyethylene-glycol (PEG) groups to epsilon-amino groups of the F(ab')(2) form of a humanized anti-interleukin-8 (anti-IL-8) antibody, we sought to decrease the in vivo clearance rate to...
5.
Napaporn J, Thomas M, Svetic K, Shahrokh Z, Brazeau G
Pharm Dev Technol
. 2000 Feb;
5(1):123-30.
PMID: 10669926
The purpose of the present study was to investigate the myotoxicity of three buffers containing carboxylic acid groups (i.e., acetate, succinate, and citrate) as a function of their pH, capacity,...
6.
Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S, et al.
J Clin Invest
. 1999 Jul;
104(2):155-62.
PMID: 10411544
TNF and Fas ligand induce apoptosis in tumor cells; however, their severe toxicity toward normal tissues hampers their application to cancer therapy. Apo2 ligand (Apo2L, or TRAIL) is a related...
7.
Shahrokh Z, Lee E, Olivero A, Matamoros R, Robarge K, Lee A, et al.
Pharm Res
. 1998 May;
15(3):434-41.
PMID: 9563074
Purpose: Alkoxycarbonylamidine prodrug modification was used to mask the positively-charged amidine moiety of an Arg-Gly-Asp peptidomimetic and enhance oral bioavailability. The aqueous stability of ethoxycarbonylamidine (ECA), ethanethiocarbonylamidine (ETCA) and phenoxycarbonylamidine...
8.
Rubas W, Cromwell M, Shahrokh Z, Villagran J, Nguyen T, Wellton M, et al.
J Pharm Sci
. 1996 Feb;
85(2):165-9.
PMID: 8683442
Confluent monolayers of Caco-2 cells, a human colonic carcinoma cell line, have been used extensively to predict intestinal absorption. A direct comparison of uptake characteristics, however, between cell monolayers and...
9.
Wang Y, Shahrokh Z, Vemuri S, Eberlein G, Beylin I, Busch M
Pharm Biotechnol
. 1996 Jan;
9:141-80.
PMID: 8914191
No abstract available.
10.
Shahrokh Z, Stratton P, Eberlein G, Wang Y
J Pharm Sci
. 1994 Dec;
83(12):1645-50.
PMID: 7891289
Denaturation, aggregation, and precipitation, which are common events in protein aging, limit the development of pharmaceutical protein formulations. Using the example of basic fibroblast growth factor (bFGF), we describe a...